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Summary
Background: Hepatitis B virus (HBV) infection is common with major clinical conse-
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quences. In Asian Americans, the HBsAg carrier rate ranges from 2% to 16% which

3

approximates the rates from their countries of origin. Similarly, HBV is the most
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important cause of cirrhosis, hepatocellular carcinoma (HCC) and liver related deaths
in HBsAg positive Asians worldwide.
Aim: To generate recommendations for the management of Asian Americans
infected with HBV.
Methods: These guidelines are based on relevant data derived from medical reports
on HBV from Asian countries as well as from studies in the HBsAg positive Asian
Americans. The guidelines herein differ from other recommendations in the treatment of both HBeAg positive and negative chronic hepatitis B (CHB), in the
approach to HCC surveillance, and in the management of HBV in pregnant women.
Results: Asian American patients, HBeAg positive or negative, with HBV DNA
levels >2000 IU/mL (>104 copies/mL) and ALT values above normal are candidates
for anti-viral therapy. HBeAg negative patients with HBV DNA >2000 IU/mL and
normal ALT levels but who have either serum albumin <3.5 g/dL or platelet count
<130 000 mm3, basal core promoter (BCP) mutations, or who have first-degree relatives with HCC should be offered treatment. Patients with cirrhosis and detectable
HBV DNA must receive life-long anti-viral therapy. Indications for treatment include
pregnant women with high viraemia, coinfected patients, and those requiring
immunosuppressive therapy. In HBsAg positive patients with risk factors, life-long
surveillance for HCC with alpha-fetoprotein (AFP) testing and abdominal ultrasound
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examination at 6-month intervals is required. In CHB patients receiving HCC treatments, repeat imaging with contrast CT scan or MRI at 3-month intervals is strongly
recommended. These guidelines have been assigned to a Class (reflecting benefit vs.
risk) and a Level (assessing strength or certainty) of evidence.
Conclusions: Application of the recommendations made based on a review of the
relevant literature and the opinion of a panel of Asian American physicians with
expertise in HBV treatment will inform physicians and improve patient outcomes.

The Handling Editor for this article was Professor Grace Wong, and it was accepted for publication after full peer-review.
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1 | INTRODUCTION

3 | QUALITY OF EVIDENCE

Hepatitis B virus infection is common and clinically consequential

This document was intended to provide recommendations regarding

worldwide. The prevalence of HBV carriers globally ranges from

the management of CHB infection in adult Asian Americans. Recom-

240 million to 300 million persons.1,2 An estimated 75% of these

mendations set forth herein have been assigned to a Class (reflecting

infected individuals reside in the Asia-Pacific region wherein HBV

benefit vs risk) and a Level (assessing strength or certainty) of evi-

is responsible for up to one-third of all cases of cirrhosis and over

dence according to the grading system set forth in the 2015 update

50% of HCC cases. HBV infection is a major public health problem

of the American College of Cardiology/American Heart Association

in the USA, especially among ethnic minorities. The prevalence of

Clinical Practice Guideline Recommendation Classification System

HBsAg positive persons in the USA is estimated to be 2.2 million

(Data S1).9

persons. Of these, 1.32 million are foreign born with 58% immigrating from high or intermediate endemic areas of Asia.3 At present, immigrants account for 95% of newly diagnosed HBV
infections in the USA.4 As a result, Asian Americans are the ethnic
group with the highest prevalence of HBV, and have the highest
rates of HCC incidence and mortality in this country. A recent
study in 400 HBsAg positive Asian American patients showed that

4 | EPIDEMIOLOGY, NATURAL HISTORY,
CLINICAL STAGES AND PROGRESSION OF
DISEASE IN ASIANS
4.1 | Prevalence of HBsAg

during a mean 84-month follow-up, 67 of 71 (94%) deaths were

Hepatitis B virus carrier rates in Asia have been reported to be as

from either liver-related complications or HCC.5 Recent reports

high as 20% in the male population of Guang Xi Province and up to

indicate that both screening for HBV in the Asian American popu-

27.5% in the Fujian Province of China.10 HBV carrier rates ranging

6,7

Despite

from 10% to 15% have been reported in Hong Kong, Shanghai, Tai-

the availability of potent anti-viral medications, improving the mor-

wan and Southeast Asia.11 According to the results of a recent study

bidity and mortality rates associated with HBV in Asian Americans

from China, HBV carrier rates have fallen to 7.2% in regions where

require greater emphasis on HBV education among health care pro-

HBV vaccination programmes have been implemented.12 The report

viders.

also indicated that the carrier rate in children <5 years of age had

lation and linkage to health care have been suboptimal.

decreased from 9.7% in 1992 to 1% in 2006, thus preventing an
estimated 16-20 million HBV carriers through HBV vaccination of

2 | METHODS

infants and young children. A similar study in Taiwan showed a
decrease in the HBV carrier rate in children from 10% in 1984 to

In April 2016, a panel of Asian American physicians with expertise

0.5% in 2009 as well as in the childhood HCC rate after implementa-

in the management of HBV convened in Pasadena, CA. Each mem-

tion of HBV vaccination of infants at birth.13 However, in other

ber was pre-assigned a section and instructed to review the rele-

parts of Asia, the HBsAg carrier rates remain high, particularly in

vant medical literature specifically aimed at Asian and Asian

countries in which HBV vaccine programmes have not yet been

Americans with hepatitis B infection. During the meeting, each

implemented. In these endemic areas, 80% of patients with chronic

topic was presented and subsequently, the manuscript was com-

hepatitis, 92% with cirrhosis, and 80% with HCC are HBsAg posi-

piled and edited (MJT). The manuscript was reviewed by the

tive.14-19

authors and a consensus on management of Hepatitis B in Asian
Americans was finalised.

Notably, the HBsAg carrier rates among Asian Americans are
similar to rates reported in their countries of origin, especially in first

Unique for Asians and Asian Americans with CHB include mater-

generation immigrants to the USA3,12,19,20 Table 1 shows a compar-

nal to child transmission (MTCT), the long period of chronicity begin-

ison of HBsAg prevalence rates derived from screening programmes

ning in the immune tolerant stage with high viraemia, presence of

in various cities in the USA, to a study which derived the HBsAg car-

genotypes B or C, and the high rate of progression to liver related

rier rates by estimating the number of foreign born persons in the

complications and HCC. More recently, disparities in HCC survival

USA and the prevalence of HBsAg carriers reported from their

was reported in a subgroup of first generation Asian immigrants to

native countries.3

the USA, specifically due to paucity of medical care, lack of hepatitis
B screening and treatments, and late stage of HCC presentation.8
Thus, the aim of this manuscript is to review the natural history,

4.2 | Routes of infection

virology and clinical characteristics as it pertains to the approach,

In high and intermediate HBV endemic areas (HBsAg prevalence

management and treatment of Asian Americans with chronic hepati-

rates of ≥8% and 2%-7% respectively) in Asia, HBV infection takes

tis B. It is anticipated that the information herein will assist physi-

place from mother to child during birth. Up to 90% of infants

cians in the day to day management of CHB in the Asian American

born to HBeAg positive mothers with high viraemia become

population.

chronically infected if immunoprophylaxis is not administered at
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T A B L E 1 The prevalence of HBsAg in Asian Americans
Country of origin

Screening in the USA
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USA. In addition, serum AFP levels are elevated in patients with

Derived from prevalence
in country of origin

acute and chronic liver diseases in the absence of HCC, especially in
the presence of ongoing necroinflammation.23,24 Elevation of AFP

China

5.6%-12.3%

12.3%

levels during ALT flares was detected in CHB-infected patients who

Vietnam

3.2%-13.6%

12.8%

eventually developed cirrhosis, and thus is another parameter to use

Philippines

5.5%-7.4%

7.4%

South Korea

5.3%

5.3%

Laos

2.3%-16.4%

11.6%

Burma

9.4%-12.4%

11.6%

Cambodian

10.3%

13.6%
12.5%

when evaluating patients for anti-viral therapy.25

4.6 | Family history of HCC
In a recent study, of 413 Asian American HBsAg positive patients,
173 with HCC and 240 without HCC were sub grouped into those

Thailand

3.9%-6.1%

Malaysia

8.8%

5.6%

associated with HCC development.25 Forty-four of 173 (25.4%) HCC

India

1.5%

3.2%

patients had 82 other blood relatives with HCC. Of these, 69

with or without a family history of HCC and analysed for risk factors

(84.1%) were first degree relatives. In a multivariate logistic regression model, a family history of HCC was an independent factor assobirth. In low endemic areas (HBsAg prevalence rates <2%), expo-

ciated with HCC development (OR = 2.58, P = 0.048). In addition, in

sure to HBV occurs primarily among adolescents and adults, in

a large population-based cohort study of 22 472 participants from

whom the carrier rate following acute infection is <5%. In Asian

Taiwan, 374 cases of incident HCC were identified during 362 268

adults, sexual contact may account for up to 10% of all HBV carri-

person-years of follow-up.26 The multivariate-adjusted hazard ratio

ers. HBV transmission also occurs at high rates among injection

for HCC for HBsAg positive individuals with family history of HCC

drug users in Asia.21

was 32.33 (P < 0.001), confirming a synergistic effect of family history and HBV on incidence of HCC.

4.3 | The phases of CHB infection
In Asian patients, the natural course of CHB infection can be divided
into five distinct phases which include the immune tolerant, immune

5 | SURVEILLANCE FOR HCC IN ASIAN
PATIENTS WITH CHB INFECTION

activation, low replication phase, reactivation and the clinical resolution phase (Figure 1). A description of the five phases is provided in

Patients with CHB infection have a > 100-fold increased risk for the

Data S2.

development of HCC compared with those without HBV infection.27,28 The annual incidence of HCC in low replication carriers is

4.4 | The clinical stages of CHB infection

estimated to be 0.5% and increases to 3%-10% in patients with cirrhosis.29 The REVEAL study from Taiwan by Chen et al demon-

Based on HBeAg status, as well as ALT and HBV DNA levels at pre-

strated a strong correlation between increasing HBV DNA levels

sentation, patients may be classified into one of several clinical

beginning at >2000 IU/mL (>104 copies/mL) and risk for HCC.27,30

22

During subsequent visits,

Another report on 820 patients with CHB infection from Hong Kong

changes in the patient’s virological and biochemical parameters may

showed that male gender, increasing age, higher HBV DNA levels,

clarify the patient’s clinical status, especially regarding the evaluation

presence of BCP mutations, and cirrhosis were independent risk fac-

of disease progression and assessment of the need for anti-viral

tors for HCC.31 In a predominantly Asian American population, risk

therapy. The six clinical stages include: HBeAg positive immune tol-

factors for HCC included older age, cirrhosis, PC mutations, BCP

erant, chronic hepatitis and cirrhosis patients, and the HBeAg nega-

mutations, and high serum AFP levels.32-34

stages of HBV infection (Figure 2).

tive low replication carrier, chronic hepatitis and cirrhosis patients.
These clinical stages are further characterised in Table S1.

A randomised controlled trial for HCC screening in >18 000 subjects in Shanghai, China showed a 37% reduction in HCC-related
mortality among patients detected by surveillance.35 Another recent

4.5 | Predictors of disease progression

study in Asian Americans with HBV showed that surveillance identified HCC patients with smaller tumour burdens and better preserved

The annual rates of progression from chronic hepatitis to cirrhosis,

liver function who were more likely to receive curative therapies

decompensated cirrhosis, HCC and death are shown on Figure S1

which prolonged survival.36

and described in Data S3. Serologic predictors of disease progression

Surveillance for HCC in all HBsAg positive patients should

in CHB patients include HBeAg, HBV genotype, HBV DNA titres,

include both AFP testing and abdominal ultrasound examination (Fig-

BCP mutants and PC mutants. A description of each of these factors

ure 3). However, lesion detection rates by ultrasound may be com-

are shown in Table S2. Tests for HBV genotype, BCP mutants and

promised by body habitus, fatty liver and cirrhosis.37 Therefore,

PC mutants are readily available at commercial laboratories in the

cross

sectional

imaging

with

contrast

enhanced

computed
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HBsAg–
anti-HBe+

anti-HBe+

HBV DNA

ALT

Immune
tolerant

Immune
activation

Low
replication

Reactivation

Resolution

Minimal
inflammation

Active
inflammation

Mild
inflammation

Active
inflammation

Inactive

Wild type
reactivation

PC mutation/
BCP mutation
Reactivation

HBeAg+
Normal ALT
DNA ++++

Immune
tolerant

Low
replication carriers

HBeAg–
Normal ALT
DNA +/–

HBeAg+
Elevated ALT
DNA +++

Chronic
hepatitis

Chronic
hepatitis

HBeAg–
Elevated ALT
DNA +++

Cirrhosis

Cirrhosis

HBeAg+
Elevated ALT
DNA ++
Albumin
Platelets

ALT: Alanine aminotransferase
HBV DNA: Hepatitis B viral DNA

HBeAg–
Elevated ALT
DNA ++
Albumin
Platelets

F I G U R E 1 The five phases of chronic
hepatitis B infection

FIGURE 2
hepatitis B

The clinical stages of

tomography (CT) or magnetic resonance imaging (MRI) should be

scan or MRI at 3-month intervals, which is based on the average

considered in a surveillance programme whenever the image quality

HCC doubling time of 4.3 months.40

of an ultrasound is suboptimal (Figure S2). HBsAg positive patients

Although debate remains regarding the optimal age to begin

at high risk for HCC development include those with more advanced

HCC surveillance, it is probably not warranted among paediatric

stage of liver disease, ie, chronic hepatitis, cirrhosis and those with

patients because of the low risk of HCC. The benefit of surveillance

blood relatives with HCC.25,38 Patients with low-to-moderate risk

in HBsAg positive males aged <40 years and females aged <50 years

include low replication carriers and immune tolerant patients. In

has not been determined. However, up to 20% of HCC cases in

addition, since patients who clear HBsAg may still develop HCC,

Asians may be in this younger age range. If clinically active chronic

surveillance should be continued, especially if cirrhosis is present at

hepatitis infection, cirrhosis or other risk factors for HCC are pre-

the time of HBsAg loss.39 The current recommendation for HCC

sent, then surveillance for HCC should be instituted.36,41,42

surveillance is every 6-12 months in immune tolerant and low repli-

Further management guidelines for liver lesions detected by

cation carriers, and every 6 months in chronic hepatitis and cirrhosis

surveillance are presented in Data S4. Confirmed cases of HCC must

patients (Figure 4). In patients with persistently elevated AFP levels

be referred to a multidisciplinary centre consisting of hepatologists,

with undetectable lesions by ultrasound examination and in patients

surgeons, interventional radiologists and oncologists who specialise

receiving HCC treatment, surveillance should include contrast CT

in the treatments of this malignancy (Table S3).43 We recommend
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levels 1–2 9 ULN, followed by lesser risks in patients with ALT levels
2–6 9 ULN, and 0.5–1 9 ULN.

6.2 | The significance of HBV DNA
The advent of PCR-based assays with improved sensitivity heralded
the era of serum HBV DNA as a marker of disease progression.
HBeAg positive patients and many HBeAg negative patients have
HBV DNA levels below 105 copies/mL.60 From 2001 through 2006,
several studies noted the development of HCC in cirrhotic and noncirrhotic patients with CHB infection with HBV DNA levels as low
as 3.7 log10 copies/mL.5,61-63 In 2006, Chen et al published a study
of 3653 HBsAg positive patients followed up for a mean of
11.4 years which showed that the incidence of HCC increased with
serum HBV DNA levels at study entry in a dose-related fashion.27 In
FIGURE 3

Ultrasound detection of a 3 cm HCC

a parallel publication, Iloeje and colleagues demonstrated a similar
relationship between serum HBV DNA and the development of cir-

that during the initial workup of a new HBsAg positive patient, a

rhosis.64 In both studies, there was an increased risk of progression

baseline abdominal ultrasound and AFP measurement should be

to cirrhosis and development of HCC at HBV DNA levels above 104

obtained. Thereafter, routine HCC surveillance with the above tests

copies/mL. Since then, additional studies have confirmed a serum

must be performed at the recommended intervals.

HBV DNA level >4 log10 copies/mL as predictive of an increased risk
for HCC development.65,66

6 | TREATMENT OF CHB INFECTION IN
ASIAN AMERICANS: PROPOSED
CANDIDATES FOR TREATMENT BASED ON
CLINICAL STAGE

6.3 | Criteria from current guidelines and new era
for a more comprehensive treatment strategy
Several recently published guidelines and an expert consensus algorithm focusing on the treatment of CHB infection are summarised in

The goal of anti-viral therapy in patients infected with HBV is to

Table S4. The difference in selection of HBV patients for anti-viral

prevent progression from chronic hepatitis to cirrhosis, end-stage

therapy in these published guidelines are discussed in Data S5. In a

liver disease, and development of HCC. The eligibility for anti-viral

long term, natural history study of predominantly Asian CHB-

therapy in recently published guidelines is based on HBeAg status,

infected patients in the USA by Tong et al, the treatment criteria

ALT values, and levels of HBV DNA in the setting of either chronic

designated in the established treatment guidelines were applied to a

hepatitis or cirrhosis.44-47

cohort of 369 HBsAg positive patients followed up for a mean of
84 months (7 years).67 Using the threshold, HBV DNA and ALT values stated in the published documents, only 20%-60% of patients

6.1 | The significance of ALT

who developed HCC and 27%-70% who died from or were trans-

Elevated serum ALT levels are indicators of hepatic necroinflammatory

planted for non-HCC-related liver complications would have been

activity. Because studies have shown that an elevated pre-treatment

identified initially as anti-viral treatment candidates. Previously, Tong

ALT level was a significant predictor of HBeAg loss or seroconversion

et al reported on a cohort of 400 CHB-infected patients in the USA

to treatments with interferon,48,49 pegylated-interferon alfa-2a,50 lami-

followed up for a mean of 83.6 months.5 The results of a multivari-

51,52

vudine (LAM),

53

and adefovir (ADV),

all of the published guidelines

ate analysis showed that older age (OR = 26.51, P = 0.007), PC

recommend anti-viral therapy for patients with CHB infection who have

mutants (OR = 4.23, P = 0.02), and BCP mutants (OR = 2.93,

elevated ALT levels. However, a significant proportion of CHB-infected

P = 0.02) were independent predictors for HCC. Additional studies

patients with normal to minimally increased ALT levels may have signifi-

on PC and BCP mutants are discussed in Data S6.

54-57

Also, a meta-analysis

Recently, Chen et al showed that lower serum albumin

demonstrated that approximately one in five patients with persistently

levels was an independent risk factor for HCC development.27 In the

normal ALT had fibrosis scores of F2 or higher.58 Finally, a study from

aforementioned study by Tong et al,67 the addition of a platelet

Hong Kong which included 3,233 CHB patients followed up for over

count <130 000 mm3 and serum albumin value <3.5 g/dL to the cri-

180 months were stratified by ALT level at presentation and during fol-

teria established by the published treatment guidelines increased the

low-up (<0.5 9 ULN, 0.5-1 9 ULN, 1-2 9 ULN, 2-6 9 ULN and

detection rate of patients eligible for treatment to 89%-100% of

>6 9 ULN) and observed for development of decompensated cirrhosis

patients who died of non-HCC liver-related causes and 96%-100%

or HCC.59 The highest risk of complications was associated with ALT

of patients who developed HCC.

cant inflammation and fibrosis on liver biopsy.
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Cirrhosis
No

Ye
s

No

Immune tolerant
Low replication carrier

No

Risk factors*
No
AFP and ultrasound
examination every
12 mo+

Yes
Yes
AFP and ultrasound
examination every
6 mo+

*Risk factors; Family history of HCC, Basal core
promoter mutant, diabetes, NASH, HCV or HIV
coinfection
**Ongoing HCC treatment
+ If ultrasound examination suboptimal,
proceed with contrast CT scan or MRI

HBV DNA

AFP
HCC**

Chronic hepatitis

AFP and CT scan
or MRI 3 mo

AFP: alpha-fetoprotein
HCC: Hepatocellular carinoma
CT: Computerized tornography
MRI: Magnetic resonance imaging

F I G U R E 4 HCC surveillance intervals in
Asian patients with hepatitis B

Other causes of ALT elevation:
Medications
Supplements
NAFLD+
Alcohol intake
Other viral etiologies ++

ALT

>ULN
≤2000 IU/mL
≤ULN

Re-evaluate in 3-6 mo

≤ULN
>2000 IU/mL

Presence of any of the following:***
Albumin <3.5 gm/dl
Platelets <130 × 103 mm3
AFP*
Basal core promoter mutant
HCC in first degree relative
≥ Fibrosis stage 2**

>ULN
ALT: Alanine aminotransferase
ULN: Upper limit of normal of clinical
laboratory
*AFP: alpha-fetoprotein
**Fibrosis score by: Liver biopsy, transient
elastrography or serum fibrosis tests
+NAFLD: nonalcoholic fatty liver disease
++Viral etiologies: HAV, HCV, HDV, HIV, EBV, CMV
***Based on data from Asian patients

Yes
Treat

6.4 | Recommendations for treatment in Asian
American patients with chronic hepatitis B

F I G U R E 5 Treatment algorithm for
HBsAg positive patients with HBeAg
positive/negative chronic hepatitis B

and HBeAg negative patients, primarily based on data from the
REVEAL-HBV study from Taiwan indicating 104 copies/mL (2000 IU/
mL) as the threshold HBV DNA level predictive of future cirrhosis

At present, anti-viral treatment is not recommended for patients who

and HCC development.27 In patients with an HBV DNA quantitation

are in the immune tolerant stage or in low replication carriers. Our

above this threshold level, determination of serum ALT is the next

guidelines are illustrated in a new algorithm, which includes additional

decision point for treatment. Patients with an ALT value > ULN in

laboratory parameters to better identify candidates for treatment to

the physician’s local laboratory in conjunction with an elevated serum

prevent disease progression (Table 2 and Figure 5). The algorithm

HBV DNA would be eligible for consideration of anti-viral therapy.

specifies a quantitative HBV DNA threshold of 2000 IU/mL as the

ALT values of 30 U/L for men and 19 U/L for women were

initial determination to consider treatment in both HBeAg positive

established as the ULN in healthy patients with the lowest risk for
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subclinical liver disease68 and are used as the ULN determination in

or higher in conjunction with inflammation would be an indication to

the AASLD guidelines and US algorithm. However, in real-world

start anti-viral therapy. In the absence of active liver inflammation

practice, ALT values often exceed these “healthy” values due to

and advanced fibrosis, anti-viral therapy can be deferred; however,

underlying factors including steatosis, dyslipidemia, obesity and med-

the patient should be monitored at least twice annually or more fre-

ications unrelated to CHB infection; therefore, these ALT values can-

quently if indicated. Other risk factors for disease progression

not be reliably interpreted to reflect inflammation due solely to HBV

include first-degree relatives with HCC.70 In addition, patients with

infection. Moreover, since “normal” ranges in clinical laboratories are

elevated AFP levels during flares of hepatitis B (without HCC) may

determined by the patient population served by that laboratory in

be more prone to have liver disease progression.25 The presence of

addition to nonstandardised assays for ALT measurement, these val-

any of these risk factors indicate that anti-viral therapy should be

ues will inherently vary between laboratories. The inclusion criteria

initiated.

used for patients treated with nucleoside/nucleotide analog anti-viral

For patients with HBV DNA levels <2000 IU/mL and ALT >ULN,

therapy in several phase 3 clinical trials were based on > ULN ALT

search for other causes of ALT elevation (ie, medications, NASH,

values derived from different clinical laboratories. Thus, the panel

excessive alcohol consumption, other viral infections, etc.). In

recommends ALT > ULN as the threshold value for treatment based

patients with HBV DNA levels <2000 IU/mL and normal ALT values,

on data from Hong Kong showing that significant inflammation and

continual evaluation should be repeated at 3-6 month intervals.

69

Recent publications report that successful NA therapies reduces

fibrosis were noted in patients with ALT 1-1.5 9 ULN.

In patients with an elevated serum HBV DNA above threshold

necroinflammation, reverses fibrosis and prevents or reverses clinical

level but serum ALT ≤ ULN, further determination is necessary

decompensation in chronic hepatitis and cirrhosis patients.71,72 The

before initiating anti-viral therapy. The next step is to assess the

benefit of reducing liver complications was demonstrated in a

patient’s serum albumin and platelet count. If the serum albumin is

prospective trial of LAM in Asian patients with compensated cirrho-

<3.5 g/dL or the platelet count is <130 000 mm , anti-viral therapy

sis.73 Benefit was primarily observed in patients with sustained viral

can be initiated. However, if serum albumin and platelet counts are

suppression; however, less significant benefit was noted in patients

persistently above threshold values, then testing to determine the

who developed LAM resistance. Other studies showed that treat-

presence of the BCP mutation is recommended. Testing for this

ment with anti-viral agents with low resistance profiles significantly

mutation should be considered even in patients who are HBeAg pos-

improved clinical outcomes in patients with decompensated cirrho-

itive, since these mutations may exist at baseline and if present, then

sis.71,74 Furthermore, a recent report indicated that the risk of HCC

anti-viral therapy can be initiated. If laboratory testing is unremark-

is significantly increased in patients with HBV-related cirrhosis with

able for hypoalbuminemia, thrombocytopenia, or BCP mutations,

low viral loads.75 Based on these findings, patients with cirrhosis

then we recommend grading and staging of liver disease with liver

who have any detectable level of HBV DNA should receive lifelong

biopsy or assessment by noninvasive methods such as transient elas-

anti-viral therapy regardless of HBeAg status or ALT values. Patients

tography or serum markers for fibrosis. The presence of F2 fibrosis

with compensated cirrhosis with undetectable HBV DNA should

3

have tests for ALT and HBV DNA every 3 months. Patients with
T A B L E 2 Recommendations for anti-viral therapy in HBeAg
positive and HBeAg negative chronic hepatitis B patients
HBeAg

HBV DNA

Comments

Immune tolerant

+

>2000 IU/mL

Insufficient
evidence to
warrant
treatment

IIb C-EO

Insufficient
evidence to
warrant
treatment

IIb C-EO

See algorithm

IA

<2000 IU/mL

Low replication
carrier

Chronic
hepatitisa

+/

Cirrhosis

+/

Decompensated
cirrhosis

+/

Hepatocellular
carcinoma

+/

>2000 IU/mL

immediately referred to a liver transplant centre.

7 | ANTI-VIRAL THERAPY
7.1 | Current treatments for HBV infection
There are currently seven drugs licensed by the FDA for the treatment of CHB infection, including standard interferon alfa-2b, LAM,
ADV, pegylated interferon alfa-2a, telbivudine, entecavir, tenofovir
disoproxil fumarate (TDF), and tenofovir alafenamide fumarate (TAF),
which represents a prodrug of the currently approved formulation of
tenofovir. Interferon alfa-2b is no longer used in the USA for the

Detectable

b

Treat

IA

treatment of HBV infection. LAM, ADV, and telbivudine are consid-

Detectable

b

Treat

I B-NR

ered second line agents and a summary of their effectiveness in

Detectable

b

HBV treatment is described in Data S7. The preferred or first-line
Treat

EO, expert opinion; NR, Non randomised studies.
Differs from APASL and AASLD guidelines.
b
Option to treat if HBV DNA undetectable.
a

Quality of
evidence

Clinical stage

decompensated cirrhosis should be started on anti-viral therapy and

IIb C-EO

agents for the treatment of CHB infection include entecavir, TDF,
and pegylated interferon alfa-2a,46 although the latter is uncommonly used in the USA. TAF was recently approved for use in the
USA in 2016 and also may be considered as a first line treatment for
CHB. In this section, we review key data governing the efficacy of
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approved agents with regard to clinical endpoints including normali-

achieving secondary endpoints including undetectable HBV DNA

sation of ALT, suppression of HBV DNA to undetectable levels,

(90% vs 72%, P < 0.001), normalisation of serum ALT (78% vs

HBeAg seroconversion, and HBsAg seroconversion. A summary of

71%, P = 0.045), and mean log reduction in serum HBV DNA (5.0

the four current agents for anti-viral treatment in Asian CHB

vs 4.5 log copies/mL, P < 0.001).83 Multiple studies have con-

patients is shown in Table 3.

firmed the long-term safety and efficacy of entecavir in USA
cohorts with sustained virological suppression to undetectable
levels and histological improvement.84,85

7.1.1 | Pegylated interferon Alfa-2a
Pegylated interferon alfa-2a (Pegasys) was licensed by the FDA for
the treatment of HBV infection in 2005. Two phase 3 clinical trials
provided the evidence base supporting approval. In the first, Lau
50

7.1.3 | Tenofovir disoproxil fumarate (TDF)
Tenofovir disoproxil fumarate is an oral nucleotide analogue, which

reported the findings in 814 HBeAg positive patients which

was licensed by the FDA for the treatment of HBV infection in

showed that after 48 weeks of treatment, pegylated interferon alfa-

2008. Two phase 3 clinical trials provided the evidence base sup-

2a alone and pegylated interferon alfa-2b plus LAM were superior to

porting FDA approval. Marcellin et al86 reported the findings of both

LAM alone in achieving HBeAg seroconversion (32% vs 27% vs

phase 3 clinical trials in which 276 treatment-na€ıve HBeAg positive

19%, P = 0.02) and suppression of HBV DNA to <100 000 copies/

patients and 375 treatment-na€ıve HBeAg negative patients were

mL (32% vs 34% vs. 22%, P = 0.003). Eight patients in each of the

randomised to receive 48 weeks of treatment with either TDF

pegylated

seroconversion,

300 mg daily or ADV 10 mg daily. TDF was superior to ADV in

whereas no patients treated with LAM alone achieved this endpoint

achieving the primary efficacy endpoint of suppression of HBV DNA

(3% vs. 3% vs. 0%, P = 0.004). In the second, Marcellin et al76

to <400 copies/mL (69 IU/mL) and histological improvement in both

et al

interferon

groups

achieved

HBsAg

reported the findings in 537 HBeAg negative patients which showed

HBeAg positive (66% vs 12%, P < 0.001) and HBeAg negative

that after 48 weeks of treatment, pegylated interferon alfa-2b alone

patients (71% vs 49%, P < 0.001). TDF was also superior to ADV for

and pegylated interferon alfa-2b plus LAM were superior to LAM

other secondary endpoints including undetectable HBV DNA (76%

alone in achieving normalisation of serum ALT (59% vs 60% vs 44%,

vs 13%, P < 0.001 in HBeAg positive patients and 93% vs 63%,

P = 0.004), and suppression of HBV DNA to <400 copies/mL (19%

P < 0.001 in HBeAg negative patients). TDF was associated with

vs 20% vs 7%, P < 0.001). Seven patients in the pegylated interferon

higher rates of normalisation of serum ALT (68% vs 54%, P = 0.03)

alone group and five patients in the pegylated interferon plus LAM

in HBeAg positive patients, but not in HBeAg negative patients

group achieved HBsAg seroconversion, whereas no patients treated

(76% vs 77%, P = 0.86). Rates of HBeAg seroconversion were not

with LAM achieved this endpoint (4% vs 2.8% vs 0%, P = 0.029).

statistically different between TDF and ADV (21% vs 18%,

Additional studies combined pegylated interferon alfa-2a with NAs

P = 0.36), although TDF was associated with a higher rate of HBsAg

such as LAM,77 ADV,78 telbivudine,79 entecavir,80 and TDF,81 but

loss (3.2% vs 0%, P = 0.02). Long-term studies have further con-

due to limited evidence, these regimens have not been incorporated

firmed the sustained safety and efficacy of TDF including virological

into practice guidelines.

suppression and histological regression at 5 years of therapy.87-89

7.1.2 | Entecavir

7.1.4 | Tenofovir alafenamide (TAF)

Entecavir is an oral NA which was licensed by the FDA for the

Tenofovir alafenamide represents a prodrug which enhances deliv-

treatment of HBV infection in 2005. Two phase 3 clinical trials

ery of active tenofovir to hepatocytes and reduces circulating levels

provided the evidence base supporting FDA approval. In the first,

of tenofovir relative to TDF, and thereby decreases the risk of

Chang et al82 reported the findings in 715 treatment-na€ıve HBeAg

renal dysfunction and bone mineral density (BMD) decline. Two

positive patients which showed that after 52 weeks of treatment,

phase 3 clinical trials provided the evidence base supporting FDA

entecavir was superior to LAM in achieving the primary efficacy

approval. Chan et al90 reported the results in 873 HBeAg positive

endpoint of histological improvement (72% vs 62%, P = 0.009), as

patients randomised 2:1 to TAF 25 mg daily (n = 581) or TDF

well as in achieving secondary endpoints including undetectable

300 mg daily (n = 292) for a period of 96 weeks. Based on a non-

HBV DNA (67% vs 36%, P < 0.001), normalisation of serum ALT

inferiority study design, no difference was observed between

(68% vs 60%, P = 0.02), and mean log reduction in serum HBV

groups in the primary therapeutic endpoint of suppression of HBV

DNA between baseline and week 48 (6.9 vs 5.4 log copies/mL,

DNA to <29 IU/mL (64% TAF vs 67% TDF, P = 0.25), or secondary

P < 0.001).82 No statistical difference was observed in HBeAg

endpoints such as normalisation of serum ALT (72% TAF vs 67%

seroconversion rates (21% vs 18%, P = 0.33). In the second, Lai

TDF, P = 0.18), HBeAg loss (14% TAF vs TDF 12%, P = 0.47),

et al

83

reported the findings in 648 HBeAg negative patients

HBeAg seroconversion (10% TAF vs 8% TDF, P = 0.32) or HBsAg

which showed that after 52 weeks of treatment, entecavir was

loss (<1% TAF vs <1% TDF, P = 0.52). Although total AEs, SAEs,

superior to LAM in achieving the primary efficacy endpoint of his-

and discontinuations due to AEs were similar between groups,

tological improvement (70% vs 61%, P = 0.01), as well as in

fewer patients on TAF experienced a > 3% decrease in bone
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T A B L E 3 Virological, biochemical and histological responses to anti-viral agents in treatment naive patients with CHB
First line agents

Asian
patients

Trial endpoints

HBeAg( )

HBV DNA

ALT

HBsAg loss /
sero-conversion

Histological
Improvement

HBeAg(+)

HBV DNA

ALT

HBeAg loss/
seroconversion

HBsAg loss/
seroconversion

Histological
Improvement

Pegylated interferon
alfa 2a (up to 45 weeks)

Entecavir
(up to 240 weeks)

Tenofovir
(up to 192 weeks)

Tenofovir
alafenamide
(up to 48 weeks)

Year 1 undetectable
HBV DNA

19%

93%

82% (ITT)

94%

Long-term undetectable
DNA

N/A

98.3%

97%

Year 1 ALT
normalisation

59%

76%

72%

Long-term ALT
normalisation

N/A

85.7%

86% (combined with
e-pos patients) @
192 weeks

Year 1 HBsAg
sero-conversion

0/0%

0/0%

Long-term HBsAg
loss/sero-conversion

0/0%

0/0%

83%

0%/0%

Year 1 histological
improvement

N/A

68%

77%

Long-term histological
improvement

N/A

100%

N/A

Year 1 undetectable
HBV DNA

14% @ 24 wk post Rx

69% (<300 c/mL)

85% (ITT)
(<400 copies/mL)

Long-term undetectable
HBV DNA

N/A

95%

97%

Year 1 ALT
normalisation

41% @ 24 wk post Rx

63%

72%

Long-term ALT
normalisation

N/A

76%

86%

Year 1 HBeAg loss/
seroconversion

31%@24 wk post Rx

16/16%

17/17%

Long-term HBeAg loss/
sero-conversion

41% @ 48 wk post Rx

40/18%

35/26%

Year 1 HBsAg
seroconversion

2% @ 24 wk post Rx

0.5%

0/0%

Long-term HBsAg loss /
sero-conversion

N/A

2.9% in genotype B
0.9% in genotype C

2.28%

Year 1 histological
improvement

38%

71%

77%

Long-term histological
improvement

N/A

100%

N/A

64% (<29 IU/mL)

72%

14/10%

<1%/0%

mineral density at week 48 in the spine (18% TAF vs 38% TDF,

endpoints such as normalisation of serum ALT (83% TAF vs 75%

P < 0.001) and hip (8% TAF vs 24% TDF, P < 0.001), and fewer

TDF, P = 0.076). Although total AEs, SAEs, and discontinuations

changes were observed in bone turnover markers. In addition, TAF

due to AEs were similar between groups, fewer patients on TAF

was associated with less change in serum creatinine (0.009 vs

experienced a > 3% decrease in bone mineral density at week 48

0.026, P = 0.02) and fewer patients with decline in the estimated

in the spine (22% TAF vs 39% TDF, P < 0.001) and hip (10% TAF

glomerular filtration rate (eGFR) to <50 mL/min (0 vs 2%,

vs 33% TDF, P < 0.001), and fewer changes were observed in

P = 0.004). Buti et al

91

reported the results in 425 HBeAg negative

bone turnover markers. The mean change in serum creatinine at

patients randomised 2:1 to TAF 25 mg daily (n = 285) or TDF

week 48 was minimal in both groups (TAF 0.01 mg/dL vs TDF

300 mg daily (n = 140) for a period of 96 weeks. Based on a non-

0.02 mg/dL, P = 0.32), but patients receiving TAF, had a smaller

inferiority study design, no difference was observed between

reduction

groups in the primary therapeutic endpoint of suppression of HBV
DNA to <29 IU/mL (94% TAF vs 93% TDF, P = 0.47), or secondary

in

creatinine

1.8 mL/min vs

clearance

(median

change

in

eGFR

4.8 mL/min, P = 0.04), with minimal changes in

markers of proximal renal tubular function. Based on a superior
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safety profile and non-inferiority of efficacy endpoints, TAF repre-

quantification may be useful in predicting HBV treatment responses,

sents an attractive alternative to TDF in the treatment of CHB.

but such tests are not widely available at present.99

7.1.5 | Treatment for decompensated cirrhosis

8.2 | Treatment duration and endpoints

The efficacy and safety of oral NAs has been studied in patients

Hepatitis B virus treatment duration with anti-viral regimens is

with decompensated cirrhosis, although the evidence base is limited

dependent on the clinical stage of disease and HBeAg status.100 The

92

Interferon alfa-2b and pegylated

with historical anti-viral agents.

decision to discontinue anti-viral therapy should be made only after

interferon alfa-2a are contraindicated in this population. Due to

careful assessment of patients’ compliance for continued monitoring

superior potency and low rates of virological resistance, and more

since only 38% of patients will maintain their clinical endpoints

robust evidence in prospective trials,71,74,93 either entecavir or TDF

within 36 months of follow-up, as described in a recent meta-analy-

are preferred agents for use in patients with decompensated cirrho-

sis of 25 studies for NA cessation.101

sis. Long-term studies documenting the impact of anti-viral therapy

The optimal duration of anti-viral therpy for HBeAg positive and

in this population on both pre-transplant and post-transplant clinical

HBeAg negative chronic hepatitis patients without cirrhosis is

outcomes (eg, hepatic decompensation, hospitalisations, HCC, liver-

unknown. Also, risk factors associated with relapse after stopping anti-

related and all-cause mortality) remain limited and would be helpful

viral therapy have not yet been identified. However, based on current

in clarifying the role and timing of treatment in this population.

information, our recommendations for duration of treatment and the
importance of close post-treatment monitoring are described below.

8 | MONITORING HBV TREATMENT

8.2.1 | HBeAg positive CHB Infection

Prior to initiating anti-viral treatment, patients should be informed

For HBeAg positive CHB infection without histological or imaging

that therapy is long-term and adherence and regular follow-up visits

evidence of advanced CHB infection, it had been recommended that

are essential. Anti-viral medications for hepatitis B are usually well

anti-viral treatment may be discontinued with at least 12-24 months

Timely prescription refills

of consolidation treatment after HBeAg seroconversion.102 However,

and appropriate patient support will improve patient compliance and

studies have indicated that HBV progression may continue after

treatment outcomes.

HBeAg seroconversion, and a substantial number of patients who

11, 93-97

tolerated with minimal side effects.

discontinue therapy after completing consolidation therapy can
experience recurrent viraemia, biochemical flares, and clinical

8.1 | Laboratory monitoring

relapse.103 In a retrospective study of 124 Chinese patients treated

After initiating anti-viral therapy, liver tests should be performed

with LAM who achieved HBeAg serconversion with HBV DNA <200

every 3 months until serum ALT levels are within normal limits and

copies/mL, the relapse rates (HBeAg servconversion) at 1 and

thereafter at 3-6 month intervals. ALT flares may occur after initia-

2 years post-treatment were 54% and 68% respectively.104 In a

tion of treatment, but usually do not require discontinuation of med-

recent report in HBeAg positive Asian American patients who dis-

ication. Renal impairment including cases of acute renal failure and

continued anti-viral therapy after loss of HBeAg and development of

Fanconi syndrome (renal tubular injury) with hypophosphatemia have

anti-HBe, 90% developed recurrent viraemia, 38% had elevated ALT

If clinically indi-

levels and 8% had seroreversion to HBeAg positivity.105 Another

cated, serum creatinine, estimated creatinine clearance, phosphorus

study of HBeAg positive Chinese patients who discontinued LAM

93

been reported in a few cases treated with TDF.

Similar

after HBeAg seroconversion showed that all patients experienced

assessment of renal function also is recommended for patients trea-

reappearance of HBV DNA and 44% of patients had ALT flares.106

ted with TAF.98 In patients receiving pegylated interferon therapy,

Due to the risk of recurrent viraemia and biochemical flares after

complete blood cell counts including absolute neutrophil and platelet

discontinuing therapy, a long-term anti-viral treatment is now recom-

counts, and thyroid function testes are required. Serum HBV DNA

mended until 6-12 months after HBsAg clearance or HBsAg sero-

should be measured using a sensitive PCR test with preferred detec-

conversion.103-105 However, if treatment discontinuation is being

tion limit of 20-50 IU/mL every 3 months until undetectable, and

considered after HBeAg seroconversion and a period of consolidated

then every 3-6 months thereafter. HBeAg positive patients on anti-

treatment but before HBsAg clearance, we recommend that the

viral treatment should have tests for HBeAg every 6 months until

patient meet the following criteria:

seronegative before initiating anti-HBe testing. HBsAg should be

1. Histological or elastography evidence of hepatic fibrosis stage <2

tested every 12 months after seroconversion from HBeAg to anti-

2. Close post-treatment monitoring at monthly intervals for the first

11,93,94

and urine glucose and protein should be measured.

11,93

Although on-treatment HBsAg clearance is rare in

3 months, and then 3-6 months thereafter. Close attention for

Asian patients, it is recommended that testing for HBsAg be per-

recurrent viraemia, with or without HBeAg seroreversion, ALT

formed every 12 months after sustained suppression of HBV DNA

elevations and clinical relapse will determine if anti-viral therapy

in HBeAg negative patients.94 Recent reports have indicated HBsAg

needs to be reinstituted. Recently, in patients treated with

HBe positive.
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entecavir, HBsAg titres of ≤2 to ≤2.5 log10 IU/mL at the time of

>1 log10 decline, but detectable HBV DNA after 3-6 months of treat-

HBeAg seroconversion were predictive of a low virological

ment. Primary nonresponse or suboptimal response may occur if:

relapse rate in Asian patients.107,108 Further studies quantifying

1. The patient is noncompliant to the treatment regimen, or is hav-

HBsAg levels will be useful in confirming these findings.

ing difficulty with prescription refills.
2. The anti-viral agent had limited potency, or

8.2.2 | HBeAg negative CHB infection
Although NA treatment is highly effective in suppressing HBV replica-

3. There is pre-existing anti-viral resistance.
These potential scenarios must be determined during clinic visits.

tion, it does not eliminate HBV infection. The recurrent viraemia rate
is high even after a long-term treatment-induced suppression of HBV
replication, and may result in biochemical flare or even hepatic decompensation. A recent systematic review study on 1732 HBeAg negative
CHB-infected patients who received anti-viral treatment reported that
1-year off-therapy virological relapse and clinical relapse occurred in
<70% and <50% of the patients, respectively, and <40% of the
patients received re-treatment.100 In patients who received 5 years of
treatment with ADV, up to 60% had virological relapse with elevated
ALT levels after stopping treatment.109 Recently, two Asian studies
also showed high relapse rates after ETV therapy. One reported a virological relapse rate of 57.8%, a clinical relapse rate of 45.2%, and a retreatment rate of 35.8% after 2 years of ETV therapy.110 Another
study reported a virological relapse rate of 91.4%, and a retreatment
rate of 88.5% after 3 years of ETV therapy.111 Therefore, for HBeAg
negative CHB patients with histological or imaging evidence of
advanced CHB infection, indefinite NA treatment is recommended to
maintain HBV DNA suppression. However, if stopping anti-viral therapy is being considered, then close follow-up with frequent laboratory
testing to detect relapse and reinstitution of anti-viral treatment is
strongly recommended. Although HBsAg loss or HBsAg seroconversion is desired, it is rarely achievable in Asian patients. If HBsAg clearance does occur, NA treatment discontinuation with close follow-up
may be considered.

8.2.5 | Virological breakthrough or rebound and
anti-viral resistance
Virological breakthrough is defined as a > 1 log10 increase from the
nadir HBV DNA (IU/mL) level while on therapy in compliant patients.
Virological rebound is defined as an increase in serum HBV DNA to
>20 000 IU/mL or above the pre-treatment baseline level during
continued therapy. Both virological breakthrough and rebound may
occur after achieving an initial virological response. Once noncompliance is excluded, virological breakthrough and rebound usually
denotes anti-viral resistance.
Hepatitis B virus anti-viral resistance can be divided into two categories; (1) genotypic resistance which refers to substitutions at conserved sites within the polymerase gene targeted by the drug, and
(2), phenotypic resistance which refers to a reduction in the in vitro
susceptibility to anti-viral agents associated with genotypic resistance.113 Anti-viral resistance can be single, multiple, or crossresistant. Cross-resistance is defined as decreased susceptibility to
more than one HBV anti-viral drug conferred by the same amino
acid substitution or combination of amino acid substitutions. The
clinical consequences of drug resistance include a reduced rate of
HBeAg seroconversion, reversal of virological and histological
improvement, an increased rate of disease progression and severe
exacerbations especially in patients with cirrhosis.114,115 The potential exists for transmission of drug resistant HBV, and for the appear-

8.2.3 | Cirrhosis
Discontinuation of anti-viral treatment in patients with cirrhosis carries a risk of hepatic decompensation or even liver failure.11,93 Furthermore, a large retrospective study indicated that even among
patients already on anti-viral therapy, a low-level viraemia, defined
as persistent or intermittent episodes of HBV DNA > than the lower
detection limit of 12 IU/mL but, <2000 IU/mL was associated with a
higher risk of developing HCC, particularly in patients with cirrhosis,
when compared to those who maintained virological response with
persistently undetectable HBV DNA levels.112 It is recommended
that all patients with baseline clinical evidence of compensated or
decompensated HBV cirrhosis, regardless of HBeAg and HBV DNA
status, remain on a life-long course of anti-viral therapy.

ance of HBsAg mutations that may lead to vaccine failure.116,117
It is recommended that any patient with a virological breakthrough or rebound undergo drug resistance analysis. Currently,
there are two types of genotypic HBV resistance tests; direct
sequencing allowing the identification of mutations that comprise
>20% of the total HBV population, and a line probe assay that identifies resistance mutations using real-time PCR analysis with specific
probes and polymorphism analysis that allows for the identification
of mutations that comprise 5% of the total HBV population. In a
recent report, up to 40% of virological breakthroughs in CHBinfected patients receiving NA were related to medication nonadherence and not anti-viral genotypic resistance.118 Thus, close
counselling of patients on adherence to their anti-viral medications
as well as confirmation of virological breakthrough and drug resis-

8.2.4 | Monitoring and managing anti-viral
treatment nonresponse or suboptimal response

tance testing are recommended to avoid unnecessary changes in
anti-viral mediations.
Table 4 summarises recommended therapy for anti-viral resis-

As summarised in Table S5, primary virological non-response to anti-

tance and cross-resistance. When a single-drug genotypic resistance

viral treatment is defined as a <1 log10 drop from baseline after

is confirmed, the preferred approach in patients with either LAM,

3 months of therapy, whereas a suboptimal response is defined as a

telbivudine, ADV or ETV resistance is to switch to TDF therapy.119
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Patients with ADV resistance may also be switched to ETV.11,93

phase. In Asian HBsAg positive children, HBeAg seroconversion is

However, switching to ADV is not recommended in patients who

uncommon and only occurs at an annual rate of less than 2% per year

developed renal dysfunction during ADV treatment. If multidrug

in infants less than 3 years of age, and at 4%-5% per year in children

resistance is identified, the combination of ETV and TDF is pre-

over the age of 3 years.129 Progression to the HBeAg positive immune

120

Recently, TDF genetic resistance was reported in a few

active phase may occur at any age in children and is accompanied by

treatment experienced Korean patients.121 However, identification

ALT elevation and inflammatory activity in the liver.130 In a recent

of a triple mutation that confers tenofovir resistance in HBV patients

report, up to 40% of children in the HBeAg positive immune active

has not yet been established.

phase experienced seroconversion to HBeAg negative and entered

ferred.

Patients with a suboptimal response to ADV may be switched to
11,93,103,122

into the low replication phase.131 In the study, approximately 50% of

those with suboptimal response to tel-

the children remained in the HBeAg positive immune tolerant phase

bivudine or LAM may be switched to TDF;11,93,119 and patients with

during the course of follow-up. Also, other reports showed that by

ETV or TDF,

123

suboptimal response to ETV may be switched to TDF.

17 years of age, 25% of Asian American children and 40% of Japanese
children had experienced spontaneous HBeAg seroconversion.131,132

9 | SPECIAL POPULATIONS

Progression to cirrhosis and development of HCC in HBsAg positive Asian children is rare. In a report from Taiwan, only three of
426 (0.7%) of chronic carrier children progressed to cirrhosis.133 Two

9.1 | Chronic hepatitis B infection during childhood
and adolescence

reports from Asia showed low rates of 0.5% to 1.5% for HCC devel-

Chronic HBV infection in children is a major health problem not only

ence of cirrhosis were risk factors for HCC in HBsAg positive

in high endemic regions, but also in Western countries with large pro-

children. The youngest reported Asian American child to develop

portions of immigrants from endemic areas, as well as in cases of

HCC was a 6-year-old male born to an HBeAg positive carrier

international adoption from regions where HBV is prevalent.124 HBV

mother.127 By the age of 3 years, a liver biopsy showed cirrhosis

exposure leading to chronicity occurs either via perinatal transmission

and seroconversion to anti-HBe positivity had already occurred.

opment.129,133 In one report, early HBeAg seroconversion and pres-

from infected mothers or during early childhood. If immunoprophy-

Anti-viral treatment is recommended for children and adolescents

laxis is not administered at birth, 90% of infants born to HBeAg posi-

who are in the HBeAg positive immune active phase of CHB, with

tive highly viremic mothers, and 5% born to HBeAg negative mothers

elevated serum ALT values and HBV DNA levels >2000 IU/

will become chronic carriers.125 In addition, 25%-50% of children

mL.124,129 The primary endpoint of therapy in HBeAg positive chil-

exposed to HBV before 5 years of age via horizontal transmission

dren is HBeAg seroconversion. Children with HBeAg negative hep-

from non-maternal sources, ie, HBsAg positive family members, also

atitis (reactivation phase) with elevated ALT levels and HBV DNA

will become chronic carriers. When infected beyond 5 years of age

levels >2000 IU/mL to >20 000 IU/mL also are recommended for

or during adolescence, 2.5%-10% become HBV carriers. HBV infec-

anti-viral treatment.124 In HBeAg negative children, the primary end-

tion during infancy and childhood is usually clinically asymptomatic

points are reduction in HBV DNA and normalisation of ALT levels.

with minimal or normal liver histological changes. However, although

Children with compensated cirrhosis with any detectable HBV DNA

rare, acute and fulminant hepatitis have been reported in Asian

value should receive immediate anti-viral treatment regardless of

infants born to HBeAg negative carrier mothers.126-128

ALT levels or HBeAg status. The primary endpoint of treatment in

Similar to adults, chronic HBV infection in children is classified into

children with compensated cirrhosis is undetectable HBV DNA. Chil-

four phases: the HBeAg positive immune tolerant and immune active

dren with decompensated cirrhosis should be immediately referred

phases, and the HBeAg negative low replication and reactivation

to liver transplant centres.

phases.129 HBsAg positive children who acquired HBV by vertical

At present, children in the HBeAg positive immunotolerant phase

transmission or during early childhood begin in the immune tolerant

are not recommended for treatment since anti-viral therapies have

T A B L E 4 Anti-viral resistance, cross resistance and recommended therapy
NA-based resistance

Common mutation sites

Resistance rates

Recommended therapy

LAM

M204V/I/S, L180M/I, M204V/I/S, A181T/V

74% at 5 years

Switch to TDF

ADV

A181T/V, N236T, I233V

29% at 3 years

Switch to TDF

LdT

M204I/V, rtA81T/V, rtL229W/V

21.6% at 2 years

Switch to TDF

ETV

M204V/I, L180M, M250V, I169T

1.2% at 6 years

Switch to TDF

TDF

No known mutation

0% at 8 years

Continue TDF

LAM+ADV

A181V and N236T

Variable

Switch to TDF

Multiple resistance

Variable combination

Variable

Switch to TDF + ETV

LAM, lamivudine; ADV, adefovir, LdT, telbivudine; ETV, entecavir; TDF, tenofovir.
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not been proven to be effective.124 Also, anti-viral therapy is not

telbivudine or TDF during pregnancy. Therefore, the authors recom-

recommended in children with HBeAg negative low replication (HBV

mend the following treatment selection for mothers, and an algo-

DNA <2000 IU/mL) “inactive carrier” phase.124,134 More detailed

rithm for anti-viral therapy during pregnancy is presented in

information for the treatment of HBV in children and adolescents

Figure 6. These recommendations are based on studies in HBsAg

are summarised in recent reports.124,129

positive pregnant Asian women.

Currently, there are five drugs that are approved for treatment

1. TDF should be considered as the first line treatment option for

of children with CHB.124 Standard interferon is approved for use in

mothers with high viraemia and started at gestational week 30,

children ages 1-17 years. Entecavir is approved for use in children 2

or earlier if maternal liver disease required treatment.

to <18 years and tenofovir is recommended for use in children ≥12

2. As the second line treatment, telbivudine may be used during

to 18 years of age. Entecavir and tenofovir have low cumulative

pregnancy. LAM should be limited to late second trimester or

rates of resistant variants of 2.6% and 0% respectively, and both

third trimester treatment for patients with HBV DNA between 6

drugs are well tolerated with minimal side effects. Lamivudine and

and 9 log10 copies/mL due to the potential for resistance and

adefovir are seldom used in the USA. Only nucleos(t)ide analogs

lower potency.139,148

should be used in children with cirrhosis.

In a retrospective study by Pan et al, a significant reduction in
the MTCT rate of HBV was observed in HBeAg positive mothers
with high viral loads when elective caesarean section was per-

9.2 | HBV infection and pregnancy

formed.149 However, further studies are warranted to confirm these

Pregnant mothers with CHB infection can vertically transmit HBV to

findings. Mothers with high viral loads who missed the opportunity

their infants,125 and if untreated, CHB infection will develop in up to

for third trimester anti-viral treatment may consider this option and

90% of infants born to HBeAg positive mothers. The combination of

careful assessment of the risk-benefit ratio with the participation of

postnatal passive and active immunisation reduces the rate of MTCT

patient’s obstetrician is recommended.

135-137

However, even with passive-active

For consultation on pre-conception, antepartum, or postpartum

immunoprophylaxis, 7%-32% of infants born to carrier mothers with

care, and infant outcomes, the discussion may include the

HBV DNA levels ≥200 000 IU/mL (≥106 copies/mL) will still become

following:

from 90% to 10%.

138-140

To reduce immunoprophylaxis failure rates

1. Treatment na€ıve patients with a treatment indication may consider

among infants born to mothers with high viral loads, anti-viral ther-

interferon therapy to seroconvert HBeAg prior to becoming preg-

HBsAg positive.

apy with TDF, LAM or telbivudine is indicated during the third trime-

nant if the pregnancy is planned more than 1 year in advance.

ster of pregnancy.141-144 Another indication for anti-viral treatment

2. For patients who are receiving oral anti-viral treatment and found

during pregnancy is maternal liver disease progression or reactiva-

to be pregnant, therapy should either be stopped or switched to

tion, especially if clinically severe.145 Candidates for anti-viral ther-

TDF

patient

was

receiving

non-TDF-based

treat-

3. Amniocentesis may increase the risk of HBV transmission in
mothers with viral loads >107 copies/mL. The decision to per-

mL) at the third trimester of pregnancy.
2. Mothers with exacerbation of ALT (>5 9 ULN of laboratory reference value), or severe fibrosis (ie, stage IV at Metavir scale;
I).

the

ment.

1. Women with HBV DNA levels ≥200 000 IU/mL (≥106 copies/

146,147

if

146,147,150

apy during pregnancy are as follows:

Anti-viral treatment can be initiated at any time point

form this procedure should be made with careful assessment on
the risk-benefit ratio for these mothers.151
4. As gestational diabetes, antepartum haemorrhage, and threatened
preterm labor frequently occur among HBV-infected mothers,

during pregnancy as indicated.
The use of LAM and telbivudine to reduce the transmission of
HBV from mothers with high viral loads during the third trimester
appears to be effective and well tolerated.139,141-143 However, highquality data are lacking. Recently, a prospective randomised control
study with TDF demonstrated that the rate of MTCT was significantly reduced from 7% to 0% when TDF was given during the third
trimester to HBeAg positive mothers with high viral loads. The
safety profiles were comparable between the TDF-treated group and
144

the control group at 28 weeks of postpartum follow-up.

Although few studies investigated the safety of using LAM or

close monitoring with at least one HBV DNA quantitative testing
at gestational week 28 is highly recommend for assessing the risk
of HBV transmission.152
5. In mothers who prefer breast-feeding, anti-viral therapy should be
discontinued since these agents may be secreted in breast milk, and
long-term data on the safety of exposing infants to anti-viral agents
are not currently available. Stopping anti-viral treatment in mothers
after delivery for lactation appears to be safe, as significant hepatitis
flares have not been observed.153-155 Postpartum monitoring on
ALT should be performed on weeks 4 and 12.144,156,157

telbivudine during the first or second trimester to control active
CHB disease, the treatment appears to be effective at normalising
ALT or reducing viraemia with a comparable safety profile146,147

9.3 | HBV coinfection with HCV or HDV

Anti-viral resistance has been reported in mothers who received

Since HBV and HCV share similar routes of transmission, coinfec-

LAM therapy, although this could be managed by switching to

tion with either virus is detected in 7%-22% of CHB-infected
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Cirrhosis/stage IV fibrosis
or severe hepatitis flare
Yes

No

Monitoring without treatment. Test HBV
DNA at end of 2nd trimester

HBV DNA <
200 000 IU/mL
(106 copies/mL)

Monitoring
without treatment

Treatment with tenofovir throughout
pregnancy

HBV DNA ≥ 200 000 IU (106 copies)/mL or
previous child with immmunoprophylaxis failure or
threatened pre-term labor

Tenofovir at
beginning of 3rd
trimester

Breatfeeding not recommended
if antiviral therapy used postpartum

All infants receive HBIG and HBV vaccination
*Recommendations based on studies
in Asian HBsAg positive women.
FIGURE 6

†Pan

CQ, et al. Semin Liver Dis 2013;33:138–146

Anti-viral therapy for mothers during pregnancy*,†

patients. Coinfection with HCV is found predominantly among indi-

Among CHB-infected Asian patients with HDV super-infection,

viduals at high risk for parenteral infection, including injection drug

lower levels of HBV DNA are common. HDV antigen or antibody

use.158 Coinfection with HDV is often seen in those residing in

tests are often used for screening. Weekly injection of pegylated

areas where HBV infection is highly endemic.159 HBV patients co-

interferon is currently used for 12-18 months to treat co-infected

infected with HCV or HDV are at higher risk for rapid progression

patients.166 The HDV RNA PCR qualitative test is available for moni-

to decompensated liver disease and HCC.160,161 In dual HBV/HCV

toring the treatment response. Sustained viral response at 6 months

infection, the treatment strategy should be directed towards the

post-treatment, which correlates better with long-term cure in the

dominant replicating virus, though HCV eradication should be con-

absence of advanced fibrosis, is only seen in 17% of patients. How-

sidered if appropriate treatment is accessible.158,162,163 When

ever, late HDV RNA relapse may occur.166

receiving direct acting anti-viral therapy for HCV infection, dual
HBV/HCV-infected patients may experience an acute exacerbation
of HBV unless anti-viral treatment for HBV is also provided.164

9.4 | HBV and HIV coinfection

The response to HBV treatment with oral anti-viral agents does

CHB infection affects nearly 15% of HIV-infected individuals. HIV

not appear to be effected by concurrent HCV infection. In addition,

accelerates the course of HBV infection to end-stage liver disease with

it has been reported that there is a risk for HBV reactivation in

more rapid progression of fibrosis.167,168 The treatment of HBV in

patients with HCV/HBV co-infection whose HCV has been cleared

HBV/HIV co-infected patients should take into account both viruses.

by direct acting anti-viral therapy (DAA).165 The FDA recently

Initiation of treatment for HBV infection is based on the presence of

issued a warning on the risk of HBV reactivation and recommend

significant fibrosis or meeting the HBV treatment criteria.169

that HCV patients should begin treatment for HBV prior to initiat-

Treatment for HBV has been shown to improve clinical out-

ing DAA therapies (https://www.fda.gov/downloads/Drugs/Drug

comes.170 In patients not requiring highly active antiretroviral ther-

Safety/UCM523499.pdf).

apy (HAART), drugs with dual activity against HBV and HIV such as
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LAM, entecavir, emtricitabine, or TDF should not be used as

2. For compensated cirrhosis patients with detectable HBV DNA,

monotherapy since these drugs may lead to mutation selection and

treat with entecavir, TDF or TAF. For decompensated cirrhotic

development of antiretroviral resistance.171,172 Pegylated interferon

patients, entecavir or TDF are currently the agents of choice (I,A).

monotherapy or ADV in combination with telbivudine may have a
168,173

3. In HBeAg negative patients with HBV DNA >2000 IU/mL (>104

In contrast, TDF and emtric-

copies/mL) and normal ALT, a liver biopsy, transient elastography

itabine or other TDF based regimens should be initiated in co-

or serum marker for fibrosis is recommended. If not available,

infected patients with low CD4 counts who require HAART.169,

172

further stratification for risk factors including measurement of

Reactivation of HBV has been observed in patients on HAART ther-

serum albumin values and platelet counts should be conducted

role in treating these patients.

apy after immune reconstitution.174

prior to treatment (IIa, C-LD).
4. To monitor treatment, test for serum ALT every 3 months. Mea-

9.5 | HBV reactivation during chemotherapy or
immunosuppressive therapy

sure HBV DNA every 3 months until negative, then every 36 months. Measure HBeAg every 6 months until negative, then
test for anti-HBe (I, C-LD).

Treatment with cancer chemotherapy or immunomodulatory agents

5. After seroconversion from HBeAg positive to anti-HBe, test for

may induce potentially fatal hepatic flares in HBsAg positive patients

HBsAg every 12 months. In HBeAg negative patients, test for

or those who are HBsAg negative but maintain a detectable level of

HBsAg every 12 months after sustained suppression of HBV

HBV DNA. The acute flare or “reactivation” results from immune

DNA (I, C-EO).

reconstitution directed towards the rise in HBV DNA following the

6. Regarding monitoring for resistance, viral breakthrough with con-

use of immunosuppressive or immunomodulating agents.175 A recent

firmation of single drug resistance requires switching to another

meta-analysis of clinical trials suggested that treatment with LAM or

first-line oral anti-viral agent (IIa, B-NR).

entecavir may prevent HBV reactivation during chemotherapy.176,177

7. Surveillance for HCC with alpha-fetoprotein and abdominal ultra-

It is recommended that Asian patients be screened for HBsAg prior

sound should be performed every 6 months in HBsAg positive

to initiation of chemotherapy or immunosuppressive therapy.

patients with chronic hepatitis, cirrhosis, and for patients with a

Patients who are HBsAg negative but anti-HBc positive should be

family history of HCC (I, B-R).

tested for HBV DNA. When the level of HBV DNA level is unde-

8. HBsAg positive pregnant women should be tested for HBV DNA.

tectable in these patients, they may have the option of being moni-

If the HBV DNA level is ≥ 200 000 IU/mL (≥106 copies/mL at

tored closely without anti-viral therapy if a moderate or low level of

gestational week 28, TDF treatment is preferred and should be

immunosuppressant therapy is used. In addition, CHB patients who

initiated at gestational week 30 (I, B-R).

will require long-term corticosteroid therapy alone or in combination

9. HBsAg positive patients or patients with any detectable levels of

with other immunosuppressive or anti-neoplastic medications, should

HBV DNA requiring chemotherapy or treatment with immunomod-

receive concomitant oral anti-viral HBV drugs.178,179 An algorithm

ulatory agents should receive anti-viral treatment (I, B-NR).

for selecting patients for anti-viral therapy is shown in Figure S3.
1. It is recommended that all HBsAg positive patients who require
chemotherapy or immunomodulatory agents should receive antiviral therapy.177
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